

# Predictors of Progression From the Appearance of Islet Childhood Diabetes: The Environmental Determinants of

Diabetes Care

38, 808-813

DOI: 10.2337/dc14-2426

Citation Report

#	ARTICLE	IF	CITATIONS
1	What defines disease in an age of genetics and biomarkers?. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 296-299.	1.2	2
2	Molecular Interactions Governing Autoantigen Presentation in Type 1 Diabetes. Current Diabetes Reports, 2015, 15, 113.	1.7	16
3	Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015, 38, 1964-1974.	4.3	690
4	Altered Macrophage and Dendritic Cell Response in <i>Mif</i> <sup>-/-</sup> Mice Reveals a Role of Mif for Inflammatory-Th1 Response in Type 1 Diabetes. Journal of Diabetes Research, 2016, 2016, 1-19.	1.0	30
5	Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio. PLoS ONE, 2016, 11, e0166702.	1.1	14
6	Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut, 2016, 65, 1061-1069.	6.1	68
7	Islet Autoantibodies. Current Diabetes Reports, 2016, 16, 53.	1.7	76
8	ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. Diabetes Technology and Therapeutics, 2016, 18, 410-414.	2.4	25
9	Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes. Current Diabetes Reports, 2016, 16, 97.	1.7	20
10	Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?. Diabetes Care, 2016, 39, 1738-1744.	4.3	19
11	Current and future efforts toward the prevention of type 1 diabetes. Pediatric Diabetes, 2016, 17, 78-86.	1.2	19
12	A novel approach for the analysis of longitudinal profiles reveals delayed progression to type 1 diabetes in a subgroup of multiple-islet-autoantibody-positive children. Diabetologia, 2016, 59, 2172-2180.	2.9	38
13	Type 1 Diabetes Prevention: A Goal Dependent on Accepting a Diagnosis of an Asymptomatic Disease. Diabetes, 2016, 65, 3233-3239.	0.3	20
14	Reversion of $\beta$ -Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. Diabetes Care, 2016, 39, 1535-1542.	4.3	56
15	Predictors of slow progression to diabetes in children with multiple islet autoantibodies. Journal of Autoimmunity, 2016, 72, 113-117.	3.0	30
16	CD4 T cell differentiation in type 1 diabetes. Clinical and Experimental Immunology, 2015, 183, 16-29.	1.1	143
17	Immune recognition and response to the intestinal microbiome in type 1 diabetes. Journal of Autoimmunity, 2016, 71, 10-18.	3.0	52
18	Genetics and its potential to improve type 1 diabetes care. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 279-284.	1.2	17

#	ARTICLE	IF	CITATIONS
19	T1D Autoantibodies. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 285-291.	1.2	17
20	Characterisation of rapid progressors to type 1 diabetes among children with HLA-conferred disease susceptibility. <i>Diabetologia</i> , 2017, 60, 1284-1293.	2.9	29
21	2. Classification and Diagnosis of Diabetes. <i>Diabetes Care</i> , 2017, 40, S11-S24.	4.3	1,420
22	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017, 66, 241-255.	0.3	454
23	Genetic Risk Scores for Type 1 Diabetes Prediction and Diagnosis. <i>Current Diabetes Reports</i> , 2017, 17, 129.	1.7	32
24	Joint modeling of longitudinal autoantibody patterns and progression to type 1 diabetes: results from the TEDDY study. <i>Acta Diabetologica</i> , 2017, 54, 1009-1017.	1.2	24
25	The Influence of Type 1 Diabetes Genetic Susceptibility Regions, Age, Sex, and Family History on the Progression From Multiple Autoantibodies to Type 1 Diabetes: A TEDDY Study Report. <i>Diabetes</i> , 2017, 66, 3122-3129.	0.3	93
26	Flexible Bayesian additive joint models with an application to type 1 diabetes research. <i>Biometrical Journal</i> , 2017, 59, 1144-1165.	0.6	15
27	Early prediction of autoimmune (type 1) diabetes. <i>Diabetologia</i> , 2017, 60, 1370-1381.	2.9	136
28	Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2881-2886.	1.8	35
29	High prevalence of diabetes-specific autoimmunity in first-degree relatives of Sardinian patients with type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2864.	1.7	9
30	10-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. <i>Journal of Clinical Investigation</i> , 2017, 127, 1757-1771.	3.9	95
31	Type 1 Diabetes: Disease Stratification. <i>Biomedicine Hub</i> , 2017, 2, 1-16.	0.4	10
32	Predicting progression to diabetes in islet autoantibody positive children. <i>Journal of Autoimmunity</i> , 2018, 90, 59-63.	3.0	17
33	A novel LIPS assay for insulin autoantibodies. <i>Acta Diabetologica</i> , 2018, 55, 263-270.	1.2	36
34	Characteristics of slow progression to diabetes in multiple islet autoantibody-positive individuals from five longitudinal cohorts: the SNAIL study. <i>Diabetologia</i> , 2018, 61, 1484-1490.	2.9	32
35	Aspectos clínicos y diagnósticos de la diabetes infantil. <i>EMC Pediatría</i> , 2018, 53, 1-22.	0.0	0
36	Electrochemiluminescence Assays for Human Islet Autoantibodies. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	4

#	ARTICLE	IF	CITATIONS
37	Risk of beta-cell autoimmunity presence for progression to type 1 diabetes: A systematic review and meta-analysis. <i>Journal of Autoimmunity</i> , 2018, 86, 9-18.	3.0	9
38	Temporal expression profiling of plasma proteins reveals oxidative stress in early stages of Type 1 Diabetes progression. <i>Journal of Proteomics</i> , 2018, 172, 100-110.	1.2	36
39	2. Classification and Diagnosis of Diabetes: <i>Standards of Medical Care in Diabetesâ€™2018</i>. <i>Diabetes Care</i> , 2018, 41, S13-S27.	4.3	2,534
40	The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update. <i>Current Diabetes Reports</i> , 2018, 18, 136.	1.7	77
41	Immune Mechanisms and Pathways Targeted in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2018, 18, 90.	1.7	29
42	Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetesâ€™The TrialNet Experience. <i>Diabetes</i> , 2018, 67, 1216-1225.	0.3	29
43	Understanding Pre-Type 1 Diabetes: The Key to Prevention. <i>Frontiers in Endocrinology</i> , 2018, 9, 70.	1.5	25
44	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , 2018, 41, 1887-1894.	4.3	104
45	Live attenuated enterovirus vaccine (OPV) is not associated with islet autoimmunity in children with genetic susceptibility to type 1 diabetes: prospective cohort study. <i>Diabetologia</i> , 2018, 61, 203-209.	2.9	5
46	Reduction in White Blood Cell, Neutrophil, and Red Blood Cell Counts Related to Sex, HLA, and Islet Autoantibodies in Swedish TEDDY Children at Increased Risk for Type 1 Diabetes. <i>Diabetes</i> , 2018, 67, 2329-2336.	0.3	15
47	Autoimmune Endocrine Disorders. , 2018, , 783-795.		1
48	Prediction and prevention of type 1 diabetes in children. <i>Clinical Pediatric Endocrinology</i> , 2019, 28, 43-57.	0.4	9
49	Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3857.	1.8	9
50	Association of HLA-dependent islet autoimmunity with systemic antibody responses to intestinal commensal bacteria in children. <i>Science Immunology</i> , 2019, 4, .	5.6	49
51	Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, 1819-1829.	0.3	12
52	Determining Antigen Specificity of Human Islet Infiltrating T Cells in Type 1 Diabetes. <i>Frontiers in Immunology</i> , 2019, 10, 365.	2.2	9
53	2. Classification and Diagnosis of Diabetes: <i>Standards of Medical Care in Diabetesâ€™2019</i>. <i>Diabetes Care</i> , 2019, 42, S13-S28.	4.3	2,164
55	Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children. <i>Pediatric Diabetes</i> , 2019, 20, 263-270.	1.2	31

#	ARTICLE	IF	CITATIONS
56	Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice. <i>Drugs</i> , 2019, 79, 43-61.	4.9	37
57	Analysis of serum Hsp90 as a potential biomarker of $\beta$ cell autoimmunity in type 1 diabetes. <i>PLoS ONE</i> , 2019, 14, e0208456.	1.1	15
58	Stem-cell based organ-on-a-chip models for diabetes research. <i>Advanced Drug Delivery Reviews</i> , 2019, 140, 101-128.	6.6	55
59	Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children. <i>Diabetes</i> , 2019, 68, 119-130.	0.3	28
60	Progression from islet autoimmunity to clinical type 1 diabetes is influenced by genetic factors: results from the prospective TEDDY study. <i>Journal of Medical Genetics</i> , 2019, 56, 602-605.	1.5	22
61	Islet autoantibodies in disease prediction and pathogenesis. <i>Diabetology International</i> , 2020, 11, 6-10.	0.7	12
62	Preclinical evaluation of antigen-specific nanotherapy based on phosphatidylserine-liposomes for type 1 diabetes. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2020, 48, 77-83.	1.9	20
63	The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. <i>Diabetologia</i> , 2020, 63, 588-596.	2.9	58
64	2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2020. <i>Diabetes Care</i> , 2020, 43, S14-S31.	4.3	2,192
65	Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado. <i>Diabetes Care</i> , 2020, 43, 1496-1503.	4.3	53
66	Association of diabetes-related autoantibodies with the incidence of asthma, eczema and allergic rhinitis in the TRIGR randomised clinical trial. <i>Diabetologia</i> , 2020, 63, 1796-1807.	2.9	8
67	Prediction and Prevention of Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2020, 11, 248.	1.5	41
68	Targeting Glycoproteins as a therapeutic strategy for diabetes mellitus and its complications. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 333-358.	0.9	14
69	2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2021. <i>Diabetes Care</i> , 2021, 44, S15-S33.	4.3	1,794
70	Insulin ist notwendig, aber nicht ausreichend: Paradigmenwechsel in der Behandlung des Typ-1-Diabetes. <i>Karger Kompass Autoimmun</i> , 2021, 3, 55-62.	0.0	0
71	Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle. <i>International Journal of Molecular Sciences</i> , 2021, 22, 932.	1.8	12
72	Islet Autoimmunity and HLA Markers of Presymptomatic and Clinical Type 1 Diabetes: Joint Analyses of Prospective Cohort Studies in Finland, Germany, Sweden, and the U.S.. <i>Diabetes Care</i> , 2021, 44, 2269-2276.	4.3	27
73	Immunological predictors of type 1 diabetes mellitus (literature review). <i>Diabetes Mellitus</i> , 2021, 24, 167-174.	0.5	0

#	ARTICLE	IF	CITATIONS
74	Preventing type 1 diabetes in childhood. <i>Science</i> , 2021, 373, 506-510.	6.0	52
75	The Multifactorial Progression from the Islet Autoimmunity to Type 1 Diabetes in Children. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7493.	1.8	11
76	Ten years follow up of first degree relatives of type 1 diabetes patients: presence of autoimmune biomarkers and the progression to diabetes in a retrospective cohort. <i>Archives of Endocrinology and Metabolism</i> , 2021, 65, 436-442.	0.3	0
77	Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. <i>Diabetologia</i> , 2021, 64, 2432-2444.	2.9	8
78	High-Affinity ZnT8 Autoantibodies by Electrochemiluminescence Assay Improve Risk Prediction for Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 3455-3463.	1.8	4
79	Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100089.	2.0	3
80	First-appearing islet autoantibodies for type 1 diabetes in young children: maternal life events during pregnancy and the child's genetic risk. <i>Diabetologia</i> , 2021, 64, 591-602.	2.9	7
81	The virome in early life and childhood and development of islet autoimmunity and type 1 diabetes: A systematic review and meta-analysis of observational studies. <i>Reviews in Medical Virology</i> , 2021, 31, 1-14.	3.9	21
82	A composite immune signature parallels disease progression across T1D subjects. <i>JCI Insight</i> , 2019, 4, .	2.3	15
83	Factors Associated With the Decline of C-Peptide in a Cohort of Young Children Diagnosed With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1380-e1388.	1.8	7
84	Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes. <i>F1000Research</i> , 2020, 9, 827.	0.8	8
85	Islet Autoantibody Measurements from Dried Blood Spots on Filter Paper Strongly Correlate to Serum Levels. <i>PLoS ONE</i> , 2016, 11, e0166213.	1.1	5
86	Is It Time to Screen the General Population for Type 1 Diabetes?. <i>US Endocrinology</i> , 2015, 11, 10.	0.3	4
87	Oxidative Stress in Autoimmune Diseases: An Under Dealt Malice. <i>Current Protein and Peptide Science</i> , 2020, 21, 611-621.	0.7	40
88	Type 1 Diabetes-related Autoantibodies in Different Forms of Diabetes. <i>Current Diabetes Reviews</i> , 2019, 15, 199-204.	0.6	30
91	Role of Heat Shock Protein 90 in Diabetes and Pancreatic Cancer Management. , 2019, , 183-195.		0
92	Diagnostic Capabilities of Islet Autoantibodies in Children with New-Onset Type 1 Diabetes Mellitus and Healthy Siblings. <i>Sovremennye Tehnologii V Medicine</i> , 2020, 12, 29.	0.4	1
93	Modeling Disease Progression Trajectories from Longitudinal Observational Data. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 668-676.	0.2	3

#	ARTICLE	IF	CITATIONS
94	GAD65 autoantibodies and glucose tolerance in offspring born to women with and without type 1 diabetes (The EPICOM study). <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 5, e00310.	1.0	2
95	Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in Children. <i>Diabetes Care</i> , 2022, 45, 160-168.	4.3	8
96	Clinical study of autoantibodies in type 1 diabetes mellitus children with ketoacidosis or microalbuminuria. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 36, e24164.	0.9	1
98	2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. <i>Diabetes Care</i> , 2022, 45, S17-S38.	4.3	1,106
99	Type 1 diabetes mellitus in pediatric age group: A rising endemic. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 27.	0.3	5
100	Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. <i>Diabetes</i> , 2022, 71, 610-623.	0.3	59
101	Multiplex agglutination-PCR (ADAP) autoantibody assays compared to radiobinding autoantibodies in type 1 diabetes and celiac disease. <i>Journal of Immunological Methods</i> , 2022, 506, 113265.	0.6	9
102	Integration of Infant Metabolite, Genetic, and Islet Autoimmunity Signatures to Predict Type 1 Diabetes by Age 6 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2329-2338.	1.8	10
103	Adult-onset type 1 diabetes: A changing perspective. <i>European Journal of Internal Medicine</i> , 2022, 104, 7-12.	1.0	6
104	Changes in the Coexpression of Innate Immunity Genes During Persistent Islet Autoimmunity Are Associated With Progression of Islet Autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY). <i>Diabetes</i> , 2022, 71, 2048-2057.	0.3	3
105	Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies. <i>Diabetologia</i> , 0, , .	2.9	5
106	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
107	Clinical and experimental treatment of type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2022, 210, 105-113.	1.1	4
108	Rising Hemoglobin A1c in the Nondiabetic Range Predicts Progression of Type 1 Diabetes As Well As Oral Glucose Tolerance Tests. <i>Diabetes Care</i> , 2022, 45, 2342-2349.	4.3	4
109	HbA1c as a time predictive biomarker for an additional islet autoantibody and type 1 diabetes in seroconverted TEDDY children. <i>Pediatric Diabetes</i> , 2022, 23, 1586-1593.	1.2	3
110	Quantifying the utility of islet autoantibody levels in the prediction of type 1 diabetes in children. <i>Diabetologia</i> , 2023, 66, 93-104.	2.9	6
111	Higher risk of severe hypoglycemia in children and adolescents with a rapid loss of C-peptide during the first 6 years after type 1 diabetes diagnosis. <i>BMJ Open Diabetes Research and Care</i> , 2022, 10, e002991.	1.2	2
112	Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering. <i>Diabetologia</i> , 0, , .	2.9	4

#	ARTICLE	IF	CITATIONS
113	Combined detection of islet autoantibodies for clinical diagnosis of type 1 diabetes in the low-prevalence population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	1.8	0
114	2. Classification and Diagnosis of Diabetes: <i>Standards of Care in Diabetes&rdquo;2023</i>. <i>Diabetes Care</i> , 2023, 46, S19-S40.	4.3	534
115	Incomplete time-series gene expression in integrative study for islet autoimmunity prediction. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	2
116	Genetic determinants of type 1 diabetes in individuals with weak evidence of islet autoimmunity at disease onset. <i>Diabetologia</i> , 2023, 66, 695-708.	2.9	0
117	Islet autoantibody screening in at-risk adolescents to predict type 1 diabetes until young adulthood: a prospective cohort study. <i>The Lancet Child and Adolescent Health</i> , 2023, 7, 261-268.	2.7	3
118	Autoimmune diseases. , 2023, , 123-244.		2
119	A perspective on treating type 1 diabetes mellitus before insulin is needed. <i>Nature Reviews Endocrinology</i> , 0, , .	4.3	2
120	Type 1 diabetes. <i>Lancet, The</i> , 2023, 401, 2149-2162.	6.3	29
121	Modulation of transcription factors by small molecules in $\beta$ -cell development and differentiation. <i>European Journal of Pharmacology</i> , 2023, 946, 175606.	1.7	2
122	Refining the Definition of Stage 1 Type 1 Diabetes: An Ontology-Driven Analysis of the Heterogeneity of Multiple Islet Autoimmunity. <i>Diabetes Care</i> , 2023, 46, 1753-1761.	4.3	2
123	Interaction Between Dietary Iron Intake and Genetically Determined Iron Overload: Risk of Islet Autoimmunity and Progression to Type 1 Diabetes in the TEDDY Study. <i>Diabetes Care</i> , 2023, 46, 1014-1018.	4.3	3
131	The Story of Diabetes and its Causes. , 2023, , 1-30.		0
133	Comments on the notion of false positivity in measurements of autoantibodies. Reply to Grill V, SÅrgjerd E, Hals I, Carlsson S [letter]. <i>Diabetologia</i> , 2024, 67, 569-570.	2.9	0